• June 24, 2022

    Paragon and its portfolio companies continue to [...]

  • May 25, 2022

    – Funding expected to provide sufficient capital [...]

  • April 5, 2022

    Expansion builds on initial strategic collaboration and [...]

  • March 1, 2022

    License agreement secures potential research of ecopipam for [...]

  • December 16, 2021

    Chicago, Dec. 16, 2021 – Paragon Biosciences has [...]

  • December 7, 2021

    Chicago, Dec. 7, 2021 – Paragon Biosciences [...]

  • November 10, 2021

    Statistically significant, clinically meaningful results obtained on the [...]

  • September 14, 2021

    Current enrollment for stuttering study is at 75%; [...]